CASP1 and cancer: Other inhibitors, including long-lasting CASP1 inhibitors49 and other angiogenesis inhibitors, may also be beneficial for treating obese cancer patients with a high basal level of neoangiogenesis as has been recently indicated50, along with current standard therapies.